Vig Pamela's most recent trade in Mirum Pharmaceuticals Inc was a trade of 30,559 Common Stock done at an average price of $34 . Disclosure was reported to the exchange on June 24, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | Pamela Vig | CHIEF SCIENTIFIC OFFICER | 24 Jun 2024 | 30,559 | 27,406 (0%) | 0% | 34 | 1,039,006 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | CHIEF SCIENTIFIC OFFICER | 24 Jun 2024 | 30,559 | 57,965 (0%) | 0% | 2.9 | 89,721 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | CHIEF SCIENTIFIC OFFICER | 24 Jun 2024 | 30,559 | 125,691 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Pamela Vig | CHIEF SCIENTIFIC OFFICER | 10 May 2024 | 94 | 27,406 (0%) | 0% | 21.0 | 1,978 | Common Stock | |
| Mirum Pharmaceuticals Inc | Vig Pamela | CHIEF SCIENTIFIC OFFICER | 02 Feb 2024 | 1,214 | 28,691 (0%) | 0% | 26.2 | 31,797 | Common Stock | |
| Mirum Pharmaceuticals Inc | Vig Pamela | CHIEF SCIENTIFIC OFFICER | 23 Jan 2024 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Pamela Vig | CHIEF SCIENTIFIC OFFICER | 23 Jan 2024 | 8,000 | 8,000 | - | - | Restricted Stock Units | ||
| Mirum Pharmaceuticals Inc | Pamela Vig | HEAD OF RESEARCH & DEVELOPMENT | 08 Jan 2024 | 1,408 | 29,905 (0%) | 0% | 28.0 | 39,472 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Head of Research & Development | 10 Nov 2023 | 527 | 31,313 (0%) | 0% | 22.3 | 11,745 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Head of Research & Development | 03 Jul 2023 | 1,425 | 30,786 (0%) | 0% | 25.6 | 36,546 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Head of Research & Development | 10 May 2023 | 684 | 32,211 (0%) | 0% | 16.9 | 11,576 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Head of Research & Development | 31 Jan 2023 | 38,500 | 38,500 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Pamela Vig | Head of Research & Development | 31 Jan 2023 | 9,625 | 31,527 (0%) | 0% | 0 | Common Stock | ||
| Mirum Pharmaceuticals Inc | Pamela Vig | CHIEF SCIENTIFIC OFFICER | 09 Jan 2023 | 1,379 | 27,312 (0%) | 0% | 20.6 | 28,438 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Head of Research & Development | 10 Nov 2022 | 660 | 21,902 (0%) | 0% | 17.1 | 11,254 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Head of Research & Development | 10 May 2022 | 807 | 21,242 (0%) | 0% | 13.6 | 10,948 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Chief Scientific Officer | 06 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Pamela Vig | Chief Scientific Officer | 06 Jan 2022 | 10,000 | 20,435 (0%) | 0% | 0 | Common Stock | ||
| Mirum Pharmaceuticals Inc | Pamela Vig | Chief Scientific Officer | 10 Nov 2021 | 768 | 10,435 (0%) | 0% | 13.5 | 10,380 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Chief Scientific Officer | 10 May 2021 | 699 | 2,906 (0%) | 0% | 14.6 | 10,219 | Common Stock | |
| Mirum Pharmaceuticals Inc | Pamela Vig | Chief Scientific Officer | 07 Jan 2021 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | ||
| Mirum Pharmaceuticals Inc | Pamela Vig | Chief Scientific Officer | 10 Nov 2020 | 595 | 2,207 (0%) | 0% | 15.3 | 9,083 | Common Stock |